What should you know about triple-negative DCIS treatment?

Ductal carcinoma in situ consists of abnormal cells confined to a milk duct. Because these cells have not invaded surrounding breast tissue, receptor language used for invasive breast cancer may not guide decisions in the same way. Ask the pathology team what was tested and how the findings affect your plan.

A mammogram often shows calcifications, and a breast biopsy samples the area for laboratory assessment. The report may describe grade, size or distribution. These details, rather than the informal phrase “triple-negative DCIS”, help the team discuss local treatment.

A lumpectomy removes the area of DCIS while preserving most of the breast; radiotherapy may follow in selected cases to reduce the chance of DCIS returning in the treated breast. A mastectomy removes the breast and may be considered when the affected area is extensive, widespread or difficult to remove with a clear margin.

Hormone therapy for cancer is generally considered only when hormone receptors are relevant and present. It is not a substitute for surgery. Your team will weigh pathology, imaging, breast size, personal preferences and reconstruction options.

Contact your breast team about a new lump, bloody nipple discharge, skin pulling, wound redness or fever after a procedure. Seek urgent care for heavy bleeding, severe breathing difficulty, chest pain or rapidly worsening swelling. A new breast change deserves assessment but does not by itself prove invasive cancer.

What grade and extent of DCIS are present? Were the margins clear after surgery? Would radiotherapy add benefit for my situation? Why is lumpectomy or mastectomy being recommended? Were hormone receptors tested, and is hormone therapy relevant?